SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop 10 kV silicon-carbide power devices is driving attention, with traders viewing it as technology validation and a potential opening in defense and infrastructure markets. The reaction is tempered by uncertainty over near-term revenue: the award is a prototype program with undisclosed financial terms, and some traders see the share move as a short-lived pop.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak surged after Zenkuda and KSI-501 met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD. Traders celebrated the results and potential for differentiated treatments, while others questioned the drugs competitive edge and flagged the remaining FDA and commercialization hurdles, cash needs, and possible dilution.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas multibillion-dollar equity investment in Summit and clinical collaboration on ivonescimab are driving attention, with many traders viewing the deal as funding and validation for the cancer drug. The reaction is largely bullish, though some caution that it is not an acquisition and that FDA approval remains uncertain, with sell-the-news concerns also surfacing.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

A sharp rally and reports of sizable buying have prompted speculation about a major investor or a potential deal, but neither a buyer nor a buyout is confirmed. Bullish traders also point to Recorlevs growth and XP-8121s Phase 3 progress, while skeptics note the drugs commercial potential remains years away.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

The FAAs review of a 737 MAX software issue has delayed MAX 10 certification, prompting concern about delivery timing and Boeings quality record. Traders are divided over the setbacks significance, with some calling it a fixable, previously known issue and others viewing it as another sign of persistent execution problems.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs AI-data-center connectivity outlook is drawing attention after Fubon initiated coverage with a Buy rating, while traders debate whether the growth case justifies its valuation. The conversation also reflects sharp swings in the shares and broader semiconductor weakness, with bulls focused on AI infrastructure demand and bears warning of further pullbacks.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Needhams new Buy coverage has drawn attention, with bullish traders citing Nano Nuclears reactor-development runway and potential AI data-center power demand. The enthusiasm is tempered by concerns about early-stage commercialization, valuation and continued weakness across speculative nuclear stocks.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas fully enrolled Phase 3 APPROACH trial of HLP003 for major depressive disorder, with topline results expected in Q4. Traders are positioning around the readout as a high-stakes catalyst, while debating the promise of earlier trial data against clinical uncertainty, possible dilution, and volatility.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Rising Treasury yields and elevated oil prices amid the Iran conflict, together with expectations of further Fed tightening, are weighing on the Dow and broader equities. Traders debate whether worsening market breadth signals deeper trouble, while some see the pullback as a buying opportunity.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoins sharp breakout and outperformance versus much of the crypto market have driven attention, with traders pointing to heavy volume and possible short covering but no broadly established catalyst. Bulls see a potential continuation higher, while skeptics warn that LTC often gives back rallies and are watching for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cabot Reports Q3 2026 Results: Full Earnings Call Transcript

Cabot (NYSE:CBT) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.
This content is powered by Benzinga APIs. Forread more...

Cabot Expands Battery Materials Platform With $50M DOE Grant

CBT plans a two-site battery materials expansion, backed by a modified $50M DOE grant, to boost U.S. conductive additives output by 2028.

Cabot Appoints Steve Delahunt As Interim CFO

(RTTNews) - Tuesday, Cabot Corp. (CBT) announced the appointment of Steve Delahunt, Vice President and Corporate Treasurer, as interim Chief Financial Officer, effective October 1, 2026...

Cabot Stock Rallies 17% in 6 Months: Here's What's Driving the Upside

CBT shares climb 16.8% in six months as Battery Materials demand, capacity expansion and cost savings support growth and cash generation.

Why Is Cabot (CBT) Down 1.6% Since Last Earnings Report?

Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reasons Why You Should Retain Cabot Stock in Your Portfolio Now

CBT is riding battery-materials growth, circular products and capacity expansion, even as weaker pricing and rising costs pressure profitability.

Major Exercise Alert: Sean D Keohane Exercises Options Worth $4.41M At Cabot

A significant insider transaction involving the exercise of company stock options was reported on August 31, by Sean D Keohane, President and CEO at Cabot (NYSE:CBT), as per the latest SEC filing.
What Happened:read more...

CBT Q3 Earnings Beat Estimates on Performance Chemicals Strength

Cabot's Q3 fiscal 2026 earnings beat estimates as Performance Chemicals gains offset Reinforcement Materials margin pressure.

Cabot Q3 2026 Earnings Call Transcript

Cabot (CBT) Tops Q3 Earnings and Revenue Estimates

Cabot (CBT) delivered earnings and revenue surprises of +0.60% and +7.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cabot Corp. is a global specialty chemicals and performance materials company. The firm's products include reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants, and aerogel. It operates through the Reinforcement Materials and Performance Chemicals segments. The Reinforcement Materials segment involves the rubber blacks and elastomer composites product lines. The Performance Chemicals segment refers to specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. The company was founded by Godfrey Lowell Cabot in 1882 and is headquartered in Boston, MA.

Cabot Corp.

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CBT Cabot Corp.

Fundamentals

Latest CBT News